InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,056.21
(
-0.28%
)
US TECH 100
16,985.60
(
-0.10%
)
Dow Jones
38,389.23
(
-0.30%
)
Brent Oil
86.95
(
-0.71%
)
Bitcoin
64,387.35
(
-3.05%
)
Post# of 251587
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 204551

Saturday, 04/22/2017 11:55:35 AM

Saturday, April 22, 2017 11:55:35 AM

Post# of 251587
JNJ/ACHN—3-DAA* HCV regimen has good-news/bad-news—mostly bad:

http://finance.yahoo.com/news/achillion-announces-additional-phase-2-070000940.html

The good news is for non-cirrhotic GT1 patients, where 6- and 8-week durations produced 100% (20/20) SVR.

The bad news is that this regimen is being discontinued as a treatment for GT3 patients, and hence it’s not in the running for a universal pan-genotypic treatment.

The SVR data for (non-cirrhotic) GT3 patients were awful: 77% (10/13) for the 12-week duration, and 0% (0/5) for the 8-week duration.

Nice call by ‘willy’ in #msg-125355802.

*Simeprevir (PI), Odalasvir (NS5A), and AL-335 (nuke).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up